Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Себорейный дерматит: возможности лечения
Себорейный дерматит: возможности лечения
Себорейный дерматит: возможности лечения. Consilium Medicum. Дерматология (Прил.). 2016; 4: 26–28.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Себорейный дерматит (СД) является одной из актуальных проблем дерматокосметологии вследствие широкого распространения, постоянного роста заболеваемости и многофакторности этиопатогенеза. На наши вопросы о возможностях лечения пациентов с себорейным дерматитом ответила врач дерматовенеролог, трихолог, член Европейской академии дерматовенерологии (EADV), кандидат медицинских наук, Марина Михайловна Юдина.
________________________________________________
Полный текст
Список литературы
1. Gupta AK, Madzia SE, Batra R. Etiology and management of Seborrheic dermatitis. Dermatology 2004; 208: 89–93.
2. Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clin Dermatol 2013; 31: 343–51.
3. Foley P, Zuo Y, Plunkett A et al. The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap). Arch Dermatol 2003; 139: 318–22.
4. Gupta AK, Bluhm R, Cooper EA et al. Seborrheic dermatitis. Dermatol Clin 2003; 21: 401–2.
5. Sampaio AL, Mameri AC, Vargas TJ et al. Seborrheic dermatitis. An Bras Dermatol 2011; 86: 1061–71.
6. Dunic I, Vesic S, Jevtovic DJ. Oral candidiasis and seborrheic dermatitis in HIV-infected patients on highly active antiretroviral therapy. HIV Med 2004; 5: 50–4.
7. Okada K, Endo Y, Fujisawa A et al. Refractory seborrheic dermatitis of the head in a patient with malignant lymphoma. Case Rep Dermatol 2014; 6: 279–82.
8. Maietta G, Fornaro P, Rongioletti F, Rebora A. Patients with mood depression have a high prevalence of seborrhoeic dermatitis. Acta Derm Venereol 1990; 70: 432–4.
9. Mastrolonardo M, Diaferio A, Logroscino G. Seborrheic dermatitis, increased sebum excretion, and Parkinson’s disease: a survey of (im) possible links. Med Hypotheses 2003; 60: 907–11.
10. Manuel F, Ranganathan S. A new postulate on two stages of dandruff: a clinical perspective. Int J Trichology 2011; 3: 3–6.
11. Schwartz JR, Cardin CW, Dawson TL. Seborrheic dermatitis and dandruff. In: Baran R, Maibach HI, editors. Textbook of Cosmetic dermatology. London: Martin Dunitz, Ltd, 2010; p. 230–41.
12. Naldi L, Rebora A. Clinical practice. Seborrheic dermatitis. N Engl J Med 2009; 360: 387–96.
13. Szepietowski JC, Reich A, Wesolowska-Szepietowska E, Baran E. National Quality of Life in Dermatology Group Quality of life in patients suffering from seborrheic dermatitis: influence of age, gender and education level. Mycoses 2009; 52: 357–63.
14. Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician 2006; 74: 125–30.
15. Viodé C, Lejeune O, Turlier V et al. Cathepsin S, a new pruritus biomarker in clinical dandruff/seborrhoeic dermatitis evaluation. Exp Dermatol 2014; 23 (4): 274–5.
16. Gemmer CM, De Angelis YM, Theelen B et al. Fast, non-invasive method for molecular detection and differentiation of Malassezia yeast species on human skin and application of the method to dandruff microbiology. J Clin Microbiol 2002; 40: 3350–7.
17. Shuttleworth D, Squire RA, Boorman GC, Goode K. Comparative clinical efficacy of shampoos containing cliclopiroxolamine (1.5%) or ketoconazole (2%; Nizoral®) for the control of dandruff/seborrhoeic dermatitis. J Dermatol Treat 1998; 9: 157–62.
18. Юдина М.М. Эффективность комбинированного шампуня, содержащего 1,5% циклопироксамин и 1% пиритион цинка, при себорейном дерматите. Consilium Medicum. Дерматология (Прил.). 2015; 4: 13–6. / Iudina M.M. Effektivnost' kombinirovannogo shampunia, soderzhashchego 1,5% tsiklopiroksamin i 1% pirition tsinka, pri seboreinom dermatite. Consilium Medicum. Dermatology (Suppl.). 2015; 4: 13–6. [in Russian]
19. Pirkhammer D, Seeber A, Hönigsmann H et al. Narrow-band ultraviolet B (ATL-01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis. Br J Dermatol 2000; 143 (5): 964–8.
2. Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clin Dermatol 2013; 31: 343–51.
3. Foley P, Zuo Y, Plunkett A et al. The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap). Arch Dermatol 2003; 139: 318–22.
4. Gupta AK, Bluhm R, Cooper EA et al. Seborrheic dermatitis. Dermatol Clin 2003; 21: 401–2.
5. Sampaio AL, Mameri AC, Vargas TJ et al. Seborrheic dermatitis. An Bras Dermatol 2011; 86: 1061–71.
6. Dunic I, Vesic S, Jevtovic DJ. Oral candidiasis and seborrheic dermatitis in HIV-infected patients on highly active antiretroviral therapy. HIV Med 2004; 5: 50–4.
7. Okada K, Endo Y, Fujisawa A et al. Refractory seborrheic dermatitis of the head in a patient with malignant lymphoma. Case Rep Dermatol 2014; 6: 279–82.
8. Maietta G, Fornaro P, Rongioletti F, Rebora A. Patients with mood depression have a high prevalence of seborrhoeic dermatitis. Acta Derm Venereol 1990; 70: 432–4.
9. Mastrolonardo M, Diaferio A, Logroscino G. Seborrheic dermatitis, increased sebum excretion, and Parkinson’s disease: a survey of (im) possible links. Med Hypotheses 2003; 60: 907–11.
10. Manuel F, Ranganathan S. A new postulate on two stages of dandruff: a clinical perspective. Int J Trichology 2011; 3: 3–6.
11. Schwartz JR, Cardin CW, Dawson TL. Seborrheic dermatitis and dandruff. In: Baran R, Maibach HI, editors. Textbook of Cosmetic dermatology. London: Martin Dunitz, Ltd, 2010; p. 230–41.
12. Naldi L, Rebora A. Clinical practice. Seborrheic dermatitis. N Engl J Med 2009; 360: 387–96.
13. Szepietowski JC, Reich A, Wesolowska-Szepietowska E, Baran E. National Quality of Life in Dermatology Group Quality of life in patients suffering from seborrheic dermatitis: influence of age, gender and education level. Mycoses 2009; 52: 357–63.
14. Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician 2006; 74: 125–30.
15. Viodé C, Lejeune O, Turlier V et al. Cathepsin S, a new pruritus biomarker in clinical dandruff/seborrhoeic dermatitis evaluation. Exp Dermatol 2014; 23 (4): 274–5.
16. Gemmer CM, De Angelis YM, Theelen B et al. Fast, non-invasive method for molecular detection and differentiation of Malassezia yeast species on human skin and application of the method to dandruff microbiology. J Clin Microbiol 2002; 40: 3350–7.
17. Shuttleworth D, Squire RA, Boorman GC, Goode K. Comparative clinical efficacy of shampoos containing cliclopiroxolamine (1.5%) or ketoconazole (2%; Nizoral®) for the control of dandruff/seborrhoeic dermatitis. J Dermatol Treat 1998; 9: 157–62.
18. Iudina M.M. Effektivnost' kombinirovannogo shampunia, soderzhashchego 1,5% tsiklopiroksamin i 1% pirition tsinka, pri seboreinom dermatite. Consilium Medicum. Dermatology (Suppl.). 2015; 4: 13–6. [in Russian]
19. Pirkhammer D, Seeber A, Hönigsmann H et al. Narrow-band ultraviolet B (ATL-01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis. Br J Dermatol 2000; 143 (5): 964–8.
2. Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clin Dermatol 2013; 31: 343–51.
3. Foley P, Zuo Y, Plunkett A et al. The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap). Arch Dermatol 2003; 139: 318–22.
4. Gupta AK, Bluhm R, Cooper EA et al. Seborrheic dermatitis. Dermatol Clin 2003; 21: 401–2.
5. Sampaio AL, Mameri AC, Vargas TJ et al. Seborrheic dermatitis. An Bras Dermatol 2011; 86: 1061–71.
6. Dunic I, Vesic S, Jevtovic DJ. Oral candidiasis and seborrheic dermatitis in HIV-infected patients on highly active antiretroviral therapy. HIV Med 2004; 5: 50–4.
7. Okada K, Endo Y, Fujisawa A et al. Refractory seborrheic dermatitis of the head in a patient with malignant lymphoma. Case Rep Dermatol 2014; 6: 279–82.
8. Maietta G, Fornaro P, Rongioletti F, Rebora A. Patients with mood depression have a high prevalence of seborrhoeic dermatitis. Acta Derm Venereol 1990; 70: 432–4.
9. Mastrolonardo M, Diaferio A, Logroscino G. Seborrheic dermatitis, increased sebum excretion, and Parkinson’s disease: a survey of (im) possible links. Med Hypotheses 2003; 60: 907–11.
10. Manuel F, Ranganathan S. A new postulate on two stages of dandruff: a clinical perspective. Int J Trichology 2011; 3: 3–6.
11. Schwartz JR, Cardin CW, Dawson TL. Seborrheic dermatitis and dandruff. In: Baran R, Maibach HI, editors. Textbook of Cosmetic dermatology. London: Martin Dunitz, Ltd, 2010; p. 230–41.
12. Naldi L, Rebora A. Clinical practice. Seborrheic dermatitis. N Engl J Med 2009; 360: 387–96.
13. Szepietowski JC, Reich A, Wesolowska-Szepietowska E, Baran E. National Quality of Life in Dermatology Group Quality of life in patients suffering from seborrheic dermatitis: influence of age, gender and education level. Mycoses 2009; 52: 357–63.
14. Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician 2006; 74: 125–30.
15. Viodé C, Lejeune O, Turlier V et al. Cathepsin S, a new pruritus biomarker in clinical dandruff/seborrhoeic dermatitis evaluation. Exp Dermatol 2014; 23 (4): 274–5.
16. Gemmer CM, De Angelis YM, Theelen B et al. Fast, non-invasive method for molecular detection and differentiation of Malassezia yeast species on human skin and application of the method to dandruff microbiology. J Clin Microbiol 2002; 40: 3350–7.
17. Shuttleworth D, Squire RA, Boorman GC, Goode K. Comparative clinical efficacy of shampoos containing cliclopiroxolamine (1.5%) or ketoconazole (2%; Nizoral®) for the control of dandruff/seborrhoeic dermatitis. J Dermatol Treat 1998; 9: 157–62.
18. Юдина М.М. Эффективность комбинированного шампуня, содержащего 1,5% циклопироксамин и 1% пиритион цинка, при себорейном дерматите. Consilium Medicum. Дерматология (Прил.). 2015; 4: 13–6. / Iudina M.M. Effektivnost' kombinirovannogo shampunia, soderzhashchego 1,5% tsiklopiroksamin i 1% pirition tsinka, pri seboreinom dermatite. Consilium Medicum. Dermatology (Suppl.). 2015; 4: 13–6. [in Russian]
19. Pirkhammer D, Seeber A, Hönigsmann H et al. Narrow-band ultraviolet B (ATL-01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis. Br J Dermatol 2000; 143 (5): 964–8.
________________________________________________
2. Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clin Dermatol 2013; 31: 343–51.
3. Foley P, Zuo Y, Plunkett A et al. The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap). Arch Dermatol 2003; 139: 318–22.
4. Gupta AK, Bluhm R, Cooper EA et al. Seborrheic dermatitis. Dermatol Clin 2003; 21: 401–2.
5. Sampaio AL, Mameri AC, Vargas TJ et al. Seborrheic dermatitis. An Bras Dermatol 2011; 86: 1061–71.
6. Dunic I, Vesic S, Jevtovic DJ. Oral candidiasis and seborrheic dermatitis in HIV-infected patients on highly active antiretroviral therapy. HIV Med 2004; 5: 50–4.
7. Okada K, Endo Y, Fujisawa A et al. Refractory seborrheic dermatitis of the head in a patient with malignant lymphoma. Case Rep Dermatol 2014; 6: 279–82.
8. Maietta G, Fornaro P, Rongioletti F, Rebora A. Patients with mood depression have a high prevalence of seborrhoeic dermatitis. Acta Derm Venereol 1990; 70: 432–4.
9. Mastrolonardo M, Diaferio A, Logroscino G. Seborrheic dermatitis, increased sebum excretion, and Parkinson’s disease: a survey of (im) possible links. Med Hypotheses 2003; 60: 907–11.
10. Manuel F, Ranganathan S. A new postulate on two stages of dandruff: a clinical perspective. Int J Trichology 2011; 3: 3–6.
11. Schwartz JR, Cardin CW, Dawson TL. Seborrheic dermatitis and dandruff. In: Baran R, Maibach HI, editors. Textbook of Cosmetic dermatology. London: Martin Dunitz, Ltd, 2010; p. 230–41.
12. Naldi L, Rebora A. Clinical practice. Seborrheic dermatitis. N Engl J Med 2009; 360: 387–96.
13. Szepietowski JC, Reich A, Wesolowska-Szepietowska E, Baran E. National Quality of Life in Dermatology Group Quality of life in patients suffering from seborrheic dermatitis: influence of age, gender and education level. Mycoses 2009; 52: 357–63.
14. Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician 2006; 74: 125–30.
15. Viodé C, Lejeune O, Turlier V et al. Cathepsin S, a new pruritus biomarker in clinical dandruff/seborrhoeic dermatitis evaluation. Exp Dermatol 2014; 23 (4): 274–5.
16. Gemmer CM, De Angelis YM, Theelen B et al. Fast, non-invasive method for molecular detection and differentiation of Malassezia yeast species on human skin and application of the method to dandruff microbiology. J Clin Microbiol 2002; 40: 3350–7.
17. Shuttleworth D, Squire RA, Boorman GC, Goode K. Comparative clinical efficacy of shampoos containing cliclopiroxolamine (1.5%) or ketoconazole (2%; Nizoral®) for the control of dandruff/seborrhoeic dermatitis. J Dermatol Treat 1998; 9: 157–62.
18. Iudina M.M. Effektivnost' kombinirovannogo shampunia, soderzhashchego 1,5% tsiklopiroksamin i 1% pirition tsinka, pri seboreinom dermatite. Consilium Medicum. Dermatology (Suppl.). 2015; 4: 13–6. [in Russian]
19. Pirkhammer D, Seeber A, Hönigsmann H et al. Narrow-band ultraviolet B (ATL-01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis. Br J Dermatol 2000; 143 (5): 964–8.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.